Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094336 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
A Phase 1 study of Advanced MTAP-null Solid Tumors, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 329
- Enrollment target
- 20
- Study locations
NCT05094336: Active Phase 1 study of Advanced MTAP-null Solid Tumors, sponsored by Amgen.
NCT05094336 is a Phase 1 study of Advanced MTAP-null Solid Tumors that is active but no longer recruiting, run by Amgen. The registered enrollment target is 329 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (448% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05094336, a Phase 1 study of Advanced MTAP-null Solid Tumors, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 329 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG AMG 193
- DRUG Comparator AMG 193 Test Tablet
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- California Research Institute - Glendale
- Fomat Medical Research - Oxnard
- University of California at SF - San Francisco
Indiana
- Goshen Health Systems - Goshen
- Indiana University - Indianapolis
- Community Health Network MD Anderson Cancer Center - North - Indianapolis
New York
- Roswell Park Cancer Institute - Buffalo
- Northwell Health Monter Cancer Center - Lake Success
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
Florida
- D and H Cancer Research Center - Margate
- Boca Raton Clinical Research Medical Center Inc - Tamarac
Maryland
- University of Maryland Medical Center - Baltimore
- American Oncology Partners, PA - Bethesda
Michigan
- Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion) - Detroit
Missouri
- Washington University - St Louis
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 1 |
What the registry record for NCT05094336 still lists
NCT05094336 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (448% higher).
The record links to 1 condition, with Advanced MTAP-null Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT05094336 names 20 study sites across 11 states, led by California, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT05094336 about?
NCT05094336 is a clinical study titled "A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)". The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioad...
What is the current status of trial NCT05094336?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 329 participants. The study started on 2022-02-01. Estimated completion is 2028-05-30.
What conditions does trial NCT05094336 study?
This clinical trial studies the following conditions: Advanced MTAP-null Solid Tumors.
What interventions are being tested in trial NCT05094336?
The interventions under investigation include: Docetaxel (DRUG), AMG 193 (DRUG), Comparator AMG 193 Test Tablet (DRUG).
Who is sponsoring clinical trial NCT05094336?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05094336 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05094336's enrollment target sits among peer trials
329 111th of 2000 higher than 1,890 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI